Business Wire

FDA Approves Genentech’s Vabysmo Prefilled Syringe (PFS) for Three Leading Causes of Vision Loss

– Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness – SOUTH SAN FRANCISCO, Calif.--(BUSINESS ...
Nasdaq

FDA Approves Genentech’s Vabysmo, the First Bispecific Antibody for the Eye, to Treat Two Leading Causes of Vision Loss

– Vabysmo (faricimab-svoa) targets and inhibits two disease pathways that drive wet age-related macular degeneration (AMD) and diabetic macular edema (DME) – – Vabysmo is the only injectable eye ...
Seeking Alpha

VABYSMO® (faricimab injection) Pre-Filled Syringe Now Publicly Funded through Ontario Drug Benefit (ODB) Program

Vabysmo now covered across all three approved indications in the province, giving patients a comprehensively funded option for their needs "We are pleased this milestone provides ophthalmologists and ...
Ad Age

Vabysmo’s animated short captures a mother’s vision loss from the POV of her child

Are you a print subscriber? Activate your account. By Asa Hiken - 27 min 25 sec ago By Ad Age Studio 30 - 1 hour 5 min ago By Adrianne Pasquarelli - 1 hour 35 min ago By Jack Neff - 2 hours 5 min ago ...
Healio

Vabysmo improves vision, reduces retinal fluid in phase 3 retinal vein occlusion studies

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Vabysmo met the primary endpoint of noninferior visual ...
Yahoo Finance

[Ad hoc announcement pursuant to Art. 53 LR] FDA approves Roche’s Vabysmo for the treatment of retinal vein occlusion (RVO)

Additional U.S. label update across indications includes information on rare post-marketing reports of retinal vasculitis and/or retinal vascular occlusion; reporting rate is in line with other ...
Pharm Exec

Fighting Vision Loss: Vabysmo

Use against pair of pathways could pave way for standout in stocked eye disease market. With Roche/Genentech’s sights set on helping patients suffering from blinding eye conditions, it turned to an ...
Business Wire

New Two-Year Data for Genentech’s Vabysmo and Susvimo Reinforce Potential to Maintain Vision With Fewer Treatments for People With Two Leading Causes of Vision Loss

‒ In the YOSEMITE and RHINE studies in diabetic macular edema, at least 60% of eligible Vabysmo patients could extend treatment to every four months at two years, compared to 50% at year one – ‒ ...
PharmiWeb

Roche’s Vabysmo maintained vision improvements with extended treatment intervals up to four months for people with retinal vein occlusion (RVO) in phase III studies

Vabysmo showed robust and sustained retinal drying up to 72 weeks and a safety profile consistent with previous studies Regulatory applications for Vabysmo in RVO are under review by health ...